TVTX · XBRL financial data

Travere Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TVTX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	45	41	54	63	75*	82	114	165	130*	127	170	225
Cost of goods and services sold	5*	2	2	2	3*	5	2	2	3*	2	2	3
Selling, general and administrative	64*	64	65	66	70*	73	76	86	102*	80	96	98
Operating income (loss)	(94)	(139)	(68)	(56)	(61)*	(43)	(13)	25	(32)*	(37)	4	(68)
Interest income	7*	6	4	4	4*	4	3	3	3*	3	3	4
Interest expense	3*	3	3	3	3*	3	3	3	2*	2	2	2
Other income (expense)	1*	0	(3)	1	(1)*	1	(1)	0	11*	(0)	(0)	(0)
Income tax expense (benefit)	0*	0	0	(0)	(0)*	0	0	0	1*	(0)	(0)	(6)
Net income (loss)	(90)	(136)	(70)	(55)	(60)*	(41)	(13)	26	3*	(37)	(35)	(52)
Earnings per share, basic USD per share	(1.18)	(1.76)	(0.91)	(0.70)	(0.73)*	(0.47)	(0.14)	0.29	0.03*	(0.40)	(0.37)	(0.55)
Earnings per share, diluted USD per share	(1.18)	(1.76)	(0.91)	(0.70)	(0.73)*	(0.47)	(0.14)	0.28	0.04*	(0.40)	(0.37)	(0.55)
Weighted average shares, basic millions of shares	76*	77	78	78	83*	88	89	89	90*	92	93	95
Weighted average shares, diluted millions of shares	76*	77	78	78	83*	88	89	103	77*	92	93	95

Fiscal quarters (TVTX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	58	43	32	36	59	62	75	111	93	78	118	124
Marketable securities	249	241	222	219	—	—	—	139	145	131	176	180
Marketable securities, non-current	260	156	71	22	—	—	—	5	84	56	196	168
Accounts receivable	21	23	24	25	27	34	39	83	80	87	81	108
Inventory	9	42	43	43	6	38	38	38	36	37	40	44
Prepaid and other current assets	19	13	13	16	13	14	17	28	29	34	37	44
Total current assets	617	481	369	325	417	374	380	371	438	393	615	633
Property and equipment, net	7	7	7	6	5	5	5	4	4	4	3	3
Right-of-use asset	18	17	16	16	14	13	12	11	11	10	9	8
Goodwill	1	1	1	1	1	1	1	1	—	—	—	—
Total assets	789	664	551	504	594	549	555	539	605	555	799	848
Accounts payable	42	17	26	23	24	15	19	18	25	13	7	15
Accrued liabilities	119	140	80	84	86	77	82	106	126	104	136	187
Total current liabilities	178	173	121	190	201	182	190	135	160	125	152	211
Lease liability, non-current	23	21	20	19	17	16	14	13	11	10	8	6
Total liabilities	588	589	536	535	535	516	523	465	490	456	775	826
Accumulated deficit	(1,126)	(1,262)	(1,332)	(1,387)	(1,447)	(1,488)	(1,501)	(1,475)	(1,473)	(1,510)	(1,545)	(1,597)
Total stockholders' equity	201	74	15	(30)	59	33	33	74	115	99	25	23
Total liabilities and equity	789	664	551	504	594	549	555	539	605	555	799	848
Common shares outstanding (cover page) millions of shares	76	76	76	78	89	89	89	89	92	93	94	96

Fiscal quarters (TVTX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(90)	(136)	(70)	(55)	(60)*	(41)	(13)	26	3*	(37)	(35)	(52)
Stock-based compensation	8*	10	10*	8*	9*	11	11*	11*	11*	16	22*	23*
Depreciation and amortization	9*	10	10*	11*	12*	13	14*	16*	18*	25	4*	5*
Net cash from operating activities	(70)*	(119)	(40)*	(43)*	(36)*	(42)	5*	14*	61*	(40)	58*	98*
Purchases of property and equipment	0*	0	0*	0*	—	—	—	0*	—	—	—	—
Net cash from investing activities	(17)*	105	29*	46*	(80)*	41	5*	87*	(105)*	22	(206)*	(120)*
Proceeds from issuing common stock	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from financing activities	0*	(1)	1*	0*	139*	4	1*	(65)*	27*	4	188*	27*
Net change in cash	(86)*	(15)	(11)*	4*	22*	3	13*	36*	(18)*	(15)	39*	6*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Mannkind	53	109	(18)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	288	59	(34)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.